Ovarian Reserve Using Anti-Mullerian Hormone in Young Women Diagnosed with Systemic Rheumatic Disease
M
Melissa Oliver, MD
Primary Investigator
Enrolling By Invitation
18 years and younger
Female
Phase
N/A
100 participants needed
2 Locations
Brief description of study
To assess ovarian reserve in adolescent patients diagnosed with Systemic Lupus Erythematosus (SLE), Juvenile Dermatomyositis (JDM), Systemic Vasculitis, and Mixed Connective Tissue Disease (MCTD), and Overlap Myositis compared to healthy adolescent females by measuring AMH levels.
Detailed description of study
Evaluate ovarian reserve with AMH levels in adolescent patients diagnosed with a systemic rheumatic condition (SLE, JDM, systemic vasculitis, MCTD, UCTD, and/or Overlap Myositis) as noted above compared to healthy adolescent females.
Hypothesis: AMH levels will be lower in patients with rheumatic disease compared to healthy controls.
- Evaluate ovarian reserve between SLE, JDM, systemic vasculitis, MCTD, UCTD, and/or Overlap Myositis patients to see if specific disease characteristics increase the risk for diminished ovarian reserve.
We will evaluate renal involvement, antiphospholipid antibody presence, exposure to gonadotoxic medications, SLEDAI (disease activity index) score, and antibody profiles.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Riley, Systemic Lupus Erythematosus (SLE), Juvenile Dermatomyositis (JDM), Systemic Vasculitis, and Mixed Connective Tissue Disease (MCTD), and Overlap Myositis
-
Age: - 18 Years
-
Gender: Female
Inclusion Criteria:
- SLE patients must meet the ACR and/or SLICC SLE classification criteria for enrollment. JDM patients must meet Peter and Bohan Criteria for enrollment. MCTD patients must meet Alarcon-Segovia Diagnostic Criteria, Kahn Criteria, Sharp Criteria, and/or Kusukawa Criteria for enrollment. ANCA vasculitis patients must meet ACR and/or EULAR/PRINTO/PRES Criteria for enrollment. Takayasu arteritis patients must meet ACR Criteria for classification for enrollment. Healthy adolescents will meet inclusion criteria if they have no chronic disease diagnosis and have been without recurrent episodes of diagnosed pelvic inflammatory disease. In both patient groups, patients will be excluded if their BMI is greater than 30, they have a previous diagnosis of PCOS, or they are currently on oral hormonal birth control, as these factors can influence AMH levels.
Exclusion Criteria:
- BMI greater than 30
- No chronic disease for healthy volunteers
- Recurrent pelvic inflammatory disease
- Previous diagnosis of PCOS
- Oral hormonal birth control
Updated on
13 Sep 2024.
Study ID: 2007877822, PRHU-IIR-2007877822
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
